Mylan (MYL) Expected to Post Quarterly Sales of $3.29 Billion
Wall Street analysts expect Mylan (NASDAQ:MYL) to report $3.29 billion in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Mylan’s earnings, with the highest sales estimate coming in at $3.38 billion and the lowest estimate coming in at $3.19 billion. Mylan reported sales of $3.27 billion in the same quarter last year, which indicates a positive year over year growth rate of 0.6%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Mylan will report full-year sales of $3.29 billion for the current fiscal year, with estimates ranging from $11.86 billion to $12.05 billion. For the next fiscal year, analysts forecast that the business will post sales of $12.62 billion per share, with estimates ranging from $12.28 billion to $13.18 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Mylan.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm’s revenue was down 2.3% on a year-over-year basis. During the same period last year, the company earned $1.38 earnings per share.
Hedge funds have recently added to or reduced their stakes in the business. Suntrust Banks Inc. grew its position in shares of Mylan by 0.7% during the 2nd quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock worth $355,000 after buying an additional 60 shares in the last quarter. Dai Ichi Life Insurance Company Ltd grew its position in shares of Mylan by 0.4% during the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 26,002 shares of the company’s stock worth $1,009,000 after buying an additional 107 shares in the last quarter. Wealthsource Partners LLC grew its position in shares of Mylan by 1.9% during the 2nd quarter. Wealthsource Partners LLC now owns 9,330 shares of the company’s stock worth $362,000 after buying an additional 177 shares in the last quarter. Accident Compensation Corp grew its position in shares of Mylan by 0.3% during the 2nd quarter. Accident Compensation Corp now owns 71,035 shares of the company’s stock worth $2,758,000 after buying an additional 200 shares in the last quarter. Finally, Riverhead Capital Management LLC grew its position in shares of Mylan by 4.8% during the 2nd quarter. Riverhead Capital Management LLC now owns 7,196 shares of the company’s stock worth $279,000 after buying an additional 328 shares in the last quarter. Institutional investors and hedge funds own 74.90% of the company’s stock.
Shares of Mylan (MYL) traded up $0.23 on Wednesday, hitting $44.54. The stock had a trading volume of 5,325,200 shares, compared to its average volume of 6,630,000. The stock has a market cap of $23,770.00, a PE ratio of 26.83, a price-to-earnings-growth ratio of 1.44 and a beta of 1.38. Mylan has a twelve month low of $29.39 and a twelve month high of $45.87. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.